Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
Parkinson's Disease, 2012 L-DOPA-induced dyskinesias (LIDs) are one of the main motor side effects of L-DOPA therapy in Parkinson's disease. The review will consider the biochemical evidence indicating that the serotonergic neurons are involved in the dopaminergic effects of L ...
Sylvia Navailles +1 more
doaj +1 more source
Synergistic Effect of Serotonin 1A and Serotonin 1B/D Receptor Agonists in the Treatment of L-DOPA-Induced Dyskinesia in 6-Hydroxydopamine-Lesioned Rats [PDF]
, 2021 Mikael S. Thomsen +4 more
openalex +1 more source
, 2011 L-DOPA is the most commonly prescribed drug for the treatment of Parkinson's disease. Here, Moor et al. (2011) report that phenylalanyl-tRNA synthetase catalyzes the misacylation of tRNAPhe by L-DOPA, suggesting that it may contribute to the elevated ...
Eric A. First, First, Eric A.
core +1 more source
Delayed O-methylation of L-DOPA in MB-COMT-deficient mice after oral administration of L-DOPA and carbidopa [PDF]
, 2017 1.Catechol-O-methyltransferase (COMT) is involved in the O-methylation of l-DOPA, dopamine, and other catechols. The enzyme is expressed in two isoforms: soluble (S-COMT), which resides in the cytoplasm, and membrane-bound (MB-COMT), which is anchored to
Anne Tammimäki +5 more
core +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression.
PLoS ONE, 2009 BackgroundThe mechanisms underlying neurotoxicity caused by L-DOPA are not yet completely known. Based on recent findings, we speculated that the increased expression of divalent metal transporter 1 without iron-response element (DMT1-IRE) induced by L ...
Fang Du +6 more
doaj +1 more source
l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
Frontiers in Pharmacology, 2019 l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine.
Yoshio Goshima +4 more
doaj +1 more source
, 1982 Urinary output of endogenous monoamine oxidase inhibitor was significantly greater in a group of postwithdrawal alcoholics than in controls. An oral dose of 0.5 g of L-dopa reduced output to control values in the alcoholics, but in the controls ...
Bhattacharya, S.K. +6 more
core
L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered
, 2019 © 2019 Elsevier Ltd In Parkinson's disease (PD), as in many other neurodegenerative disorders, mitochondrial dysfunction, protein misfolding, and proteotoxic stress underly the disease process.
Djordjevic, SP +4 more
core +1 more source
Atomically precise metal cluster enzymes for pathological tissue regeneration
BMEMat, EarlyView.Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong +11 more
wiley +1 more source